<DOC>
	<DOCNO>NCT00733343</DOCNO>
	<brief_summary>The purpose trial evaluate long-term effect cost-effectiveness adaptive servo-ventilation ( ASV ) mortality morbidity patient stable heart failure due leave ventricular systolic dysfunction , already receive optimal medical therapy , sleep disorder breathing ( SDB ) predominantly central sleep apnea . Assumptions : intervention reduce hazard rate 20 % . The event rate control group 35 % first year . It assume hazard rate constant time .</brief_summary>
	<brief_title>Treatment Predominant Central Sleep Apnoea Adaptive Servo Ventilation Patients With Heart Failure</brief_title>
	<detailed_description>Objective : The purpose trial evaluate long-term effect cost-effectiveness adaptive servo-ventilation ( ASV ) mortality morbidity patient stable heart failure due leave ventricular systolic dysfunction , already receive optimal medical therapy , sleep disorder breathing ( SDB ) predominantly central sleep apnea . Study Design : Randomized , multicentre , international trial parallel group design , patient randomize either control ( optimal medical management ) active treatment ( optimal medical treatment plus use adaptive servoventilation ) 1:1 ratio . There sham-positive airway pressure treatment control arm . Assumptions : intervention reduce hazard rate 20 % . The event rate control group 35 % first year . It assume hazard rate constant time . The trial event drive design : final analysis perform late 651 event observe . The primary analysis intention-to-treat population consist patient randomize . Number Patients : 1116 patient randomly assign one two treatment group . A 20 % drop rate estimate . Selection criterion : Patients age 22 year severe chronic heart failure ( chronic HF ) , NYHA class III-IV NYHA class II least one hospitalization HF within last 24 month , Left Ventricular Ejection Fraction ( LVEF ) less equal 45 % mean echocardiography , radionuclidventriculography cardiac MRI Sleep Disordered Breathing ( SDB ) ( apnoea-hypopnoea-index ( AHI &gt; 15/h ) 50 % central event central AHI ≥ 10/h , change medication hospitalization 1 month randomization medical therapy accord applicable guideline ( European Society Cardiology ( ESC ) American College Cardiology/American Heart Association ( ACC/AHA ) respectively ) . Primary Endpoints : Time first event : 1. cause mortality unplanned hospitalisation/prolongation hospitalisation worsen heart failure 2. cardiovascular mortality unplanned hospitalisation/prolongation hospitalisation worsen heart failure . 3. cause mortality cause unplanned hospitalisation/prolongation hospitalisation Heart transplantation , appropriate shock ICD , long term assist device ( LTAD ) insertion survive resuscitation sudden cardiac arrest count cardiovascular death , survive resuscitation reason count cause death . The three combination test parallel hierarchical order . Secondary Endpoints : Time death , non cardiovascular death , cardiovascular death , hospitalization due deterioration heart failure cardiovascular death , hospitalization reason death , hospitalization cardiovascular cause cardiovascular death , percent follow day patient survive hospitalized cardiovascular cause , percent follow day patient survive hospitalized reason , time first adequate shock ( patient ICD , evaluation appropriateness also make ERC ) cardiovascular death , change NYHA class compare baseline , change difference health cost two treatment group , change QoL ( Minnesota , Euroqol 5D ( EQ5D ) ) compare baseline , change renal function ( base serum creatinine ) compare baseline , change result Six Minute Walking Test ( 6MWT ) ( 50 ) compare baseline , change AHI oxygen desaturation index compare baseline , AHI 10 per hour twelve month ODI 5 per hour twelve month , atrial fibrillation follow-up visit . Number cost hospitalization ( tariff/DRG , diagnose procedure calculate DRG length stay level care provide ) , cost care ( technology service , nursing , physician visit ) relate ventilation , difference utility / QoL ( Minnesota EQ5D ) compare control arm , difference cost resource consume , cost-efficacy , cost-utility . Secondary target parameter measure last follow last available observation within FU . Scheduled follow : Minimum follow time 24 month , maximum 70 month . There final assessment patient end study .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Sleep Apnea Syndromes</mesh_term>
	<mesh_term>Respiratory Aspiration</mesh_term>
	<mesh_term>Sleep Apnea , Central</mesh_term>
	<criteria>Patients must least 22 year old Chronic heart failure ( least 12 week since diagnosis ) accord current applicable guideline ( ESC , ACC/AHA ) Left ventricular systolic dysfunction ( LVEF ≤45 % image method echocardiography , radionuclide angiography , leave ventriculography , cardiac magnetic resonance imaging ) document less 12 week randomisation NYHA class III IV time inclusion NYHA class II least one hospitalisation HF last 24 month No hospitalisation heart failure least 4 week prior inclusion Optimised medical treatment accord applicable guideline new class disease modify drug 4 week prior randomisation . In case beta blocker ACE inhibitors/ ARB antagonist reason must document SDB ( AHI &gt; 15/h ≥ 50 % central event central AHI ≥ 10/h , derive polygraphy polysomnography ( base total record time ( TRT ) ) , document less 4 week randomisation . Flow measurement perform nasal cannula Patients use AutoSet CS2/VPAP Adapt may contraindicate symptomatic hypotension significant intravascular volume depletion pneumothorax pneumomediastinum Patient able fully understand study information sign informed consent Significant COPD Forced Expiratory Volume within one second ( FEV1 ) &lt; 50 % ( European Respiratory Society criterion ) last four week randomisation Oxygen saturation rest day ≤ 90 % inclusion Current use Positive Airway Pressure ( PAP ) therapy Life expectancy &lt; 1 year disease unrelated chronic HF Cardiac surgery , Percutaneous coronary intervention ( PCI ) , Myocardial Infarction ( MI ) unstable angina within 6 month prior randomisation CRTimplantation ICDimplantation schedule within 6 month prior randomisation Transient ischemic attack ( TIA ) Stroke within 3 month prior randomisation Primary hemodynamically significant uncorrected valvular heart disease , obstructive regurgitant , valvular disease expect lead surgery trial Acute myocarditis/pericarditis within 6 month prior randomisation Untreated therapy refractory Restless legsSyndrome ( RLS ) accord criterion list Appendix IX time study entry Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>22 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>heart failure</keyword>
	<keyword>sleep disorder breathing</keyword>
	<keyword>sleep apnea</keyword>
	<keyword>leave ventricular systolic dysfunction</keyword>
	<keyword>SBAS</keyword>
	<keyword>HF</keyword>
</DOC>